INVESTOR PROFILE | Ionic Brands
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
52-Week
Range N/A
Range N/A
Current
Outstanding 108,436,715
Outstanding 108,436,715
Warrants
Options
Fully Diluted
Market Cap.
14,639,000
14,639,000
IONIC BRANDS (CSE: IONC) has a premium portfolio of cannabis concentrate consumer brands. Ionic Brands is one of the top selling concentrate company in Washington State.
Company Brief
Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands.
They have:
- Stylish products
- World Class Management Team
- A proven and repeatable strategy for success
Highlights
Experienced and proven luxury cannabis concentrates brand
One of the tops selling vape brands in WA State with a loyal customer base
Largest standalone oil manufacturer in the state of WA
Consistent sales growth over 3 years with a verified marketing blueprint
Offers investors exposure to a premium luxury cannabis brand
Demonstrated to have a winning formula to become the top vape company in WA
Massive growth opportunity available with expansion into OR, NV and CA
In The News
Ionic Is Changing the Face of Cannabis and Creating a Social Revolution
It’s all in the URL: Ionic.social. “We believe our products are best when enjoyed in a social setting,” said co-founder Christian Struzan.
READ MORE
Marijuana Vaping Is The Most Explosive Growth Play In Marijuana Today
“Nobody smokes marijuana anymore, they vape it.” - New York Times That's not quite true. But it will be soon.
READ MORE
How To Invest In Marijuana Vaping
The marijuana vaporization products (or just "vape") market is set to explode in 2019.
READ MORE
Related Articles
Novamind Expands Group Therapy Model
Novamind announces plans to expand group therapy within its clinical therapy model.
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
Mydecine reports conditional approval to commence a Phase IIb study on smoking cessation, in partnership with Johns Hopkins University.
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease
Pharmather reports positive tolerability and dose-finding results in its clinical trial of a ketamine-based drug for Parkinson's disease as it prepares for a Phase III trial.
The War AGAINST Mental Health: 50 Years Of Failure And Corruption
For 50 years Western governments have relentlessly undermined the mental health of their citizens while also criminalizing the only effective drugs for treating mental health.
Revitalist Launches UNIT Initiative Working With Veteran and First Responder Non-Profits Across the United States Creating Nationwide Guidelines
Revitalist Lifestyle and Wellness announces a new initiative focusing on providing access to mental health therapies for veterans and first-responders.